曲安奈德在增生性玻璃体视网膜病变中应用的研究进展  

Progress of triamcinolone acetonide in the treatment of proliferative vitreoretinopathy

作　　者：郭海霞 于金国[1] 颜华[1] GUO Haixia;YU Jinguo;YAN Hua(Department of Ophthalmology,General Hospital of Tianjin Medical University,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院,天津市300052

出　　处：《眼科新进展》2021年第10期992-995,1000,共5页Recent Advances in Ophthalmology

基　　金：天津医科大学总医院青年孵育项目(编号ZYYFY2018013)。

摘　　要：增生性玻璃体视网膜病变(PVR)在孔源性视网膜脱离、眼外伤以及玻璃体切割手术后均可能发生。曲安奈德(TA)作为一种长效糖皮质激素在PVR的预防和抑制中具有一定的效果。本文就TA在PVR预防和抑制中的分子机制、体外实验、体内实验、临床应用进展进行综述,以期为今后TA更好应用提供一定帮助。Occurrence of proliferative vitreoretinopathy(PVR)is common in rhegmatogenous retinal detachment,ocular trauma and post pars plana vitrectomy.As a long-acting glucocorticoid,triamcinolone acetonide(TA)has been proven to prevent and inhibit PVR effectively.Hence,the molecular mechanism,in vitro experiment,in vivo experiment and clinical application of TA in the prevention and inhibition of PVR are reviewed,hoping to promote the better application of TA on ocular diseases in the near future.

关 键 词：增生性玻璃体视网膜病变 曲安奈德 分子机制 

分 类 号：R774.1[医药卫生—眼科]